Navigation Links
Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
Date:10/22/2008

SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) (the "Company") is an emerging biotechnology leader specializing in the commercialization of medical cannabis-based pharmaceutical products. Today the Company is pleased to announce it has signed an agreement to acquire all of the assets of Cannex, a privately owned California group operated by Medical Cannabis pioneer and political activist Steven W. Kubby (http://www.kubby.com). The asset purchase agreement includes all intellectual property rights, formulas, patents, trademarks, client base, hardware and software, etc... pertaining to Cannex's pharmaceutical cannabis research & development business. Dynamic Alert anticipates closing this transaction upon completion of a 90-day due diligence period.

Richard Cowan, Dynamic President & CEO, stated, "Mr. Kubby's background in the medical cannabis arena is simply put, the living proof that it works. Mr. Kubby, the founder of Cannex, is a long-term cancer survivor. Mr. Kubby is an entrepreneur with a wide range of experience and success in businesses ranging from property management to publishing to political fundraising. He received his BA in Psychobiology from California State University. Kubby is a survivor, for more than three decades, of a rare form of adrenal cancer with a mortality prognosis of 6-12 months. Leading specialists in the US and Canada have attributed his survival to medical cannabis. Mr. Kubby is a director of the American Medical Marijuana Association, an internationally recognized organization comprised of doctors, lawyers, nurses and patients working for the rights of medical cannabis patients primarily in the United States. Having been a leader in the passing of California's medical cannabis initiative (Proposition 215) in 1996, Kubby is intimately familiar with the legal and regulatory problems involved in developing and marketing cannabinoid-based pharmaceuticals."

As well, Dynamic Alert has just appointed world-renowned Medical Cannabis Research expert Dr. Robert Melamede as its newest Director and Chief Science Officer. Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach and research cannabinoids, cancer, and DNA repair. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. Please visit http://www.youtube.com/watch?v=n31Nuj_AvTg to view one of many video speeches by Dr. Robert Melamede speaking on the effectiveness of Medical Cannabinoids.

Dynamic Alert President & CEO, Richard Cowan added, "This is truly a great step for Dynamic Alert, because this transaction and the addition of Dr. Melamede to our team will certainly expedite our plans to bring critical pharmaceutical cannabis products to market. Cannex has several innovative formulations in various stages development, including a lozenge that has just gone through informal human trials by a Canadian Compassion Society with outstanding results. We have updated our website, http://www.dynamicalertlimited.com/ to keep our shareholders informed as we progress through our plans to become a leader in pharmaceutical cannabis products."

You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as "will", "anticipates", "believes", "plans", "goal", "expects", "future", "intends" and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release.


'/>"/>
SOURCE Dynamic Alert Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
2. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
3. Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
4. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
5. Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub
6. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
7. Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
8. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
9. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
10. U.S. Army Awards General Dynamics Contract for Biological Detection System Production and Support
11. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... USA, and CARDIFF, UK (PRWEB) , ... February ... ... international society for optics and photonics , have been named Fellows of the ... significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):